SINOPHARM GROUP 1/5/O.N. (X2S1) - Total Assets
Based on the latest financial reports, SINOPHARM GROUP 1/5/O.N. (X2S1) holds total assets worth €390.36 Billion EUR (≈ $456.37 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See X2S1 total equity for net asset value and shareholders' equity analysis.
SINOPHARM GROUP 1/5/O.N. - Total Assets Trend (2021–2025)
This chart illustrates how SINOPHARM GROUP 1/5/O.N.'s total assets have evolved over time, based on quarterly financial data. Check SINOPHARM GROUP 1/5/O.N. (X2S1) asset resilience to evaluate the company's liquid asset resilience ratio.
SINOPHARM GROUP 1/5/O.N. - Asset Composition Analysis
Current Asset Composition (December 2025)
SINOPHARM GROUP 1/5/O.N.'s total assets of €390.36 Billion consist of 88.8% current assets and 11.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.5% |
| Accounts Receivable | €194.61 Billion | 49.9% |
| Inventory | €63.34 Billion | 16.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.36 Billion | 1.1% |
| Goodwill | €5.78 Billion | 1.5% |
Asset Composition Trend (2021–2025)
This chart illustrates how SINOPHARM GROUP 1/5/O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SINOPHARM GROUP 1/5/O.N. (X2S1) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SINOPHARM GROUP 1/5/O.N.'s current assets represent 88.8% of total assets in 2025, an increase from 86.7% in 2021.
- Cash Position: Cash and equivalents constituted 12.5% of total assets in 2025, down from 13.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 49.9% of total assets.
SINOPHARM GROUP 1/5/O.N. Competitors by Total Assets
Key competitors of SINOPHARM GROUP 1/5/O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jointown Pharmaceutical Group Co Ltd
SHG:600998
|
China | CN¥112.28 Billion |
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$8.80 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3
|
Brazil | R$5.64 Billion |
|
Cyclopharm Ltd
AU:CYC
|
Australia | AU$46.10 Million |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
China | CN¥235.37 Billion |
SINOPHARM GROUP 1/5/O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.39 | 1.35 |
| Quick Ratio | 1.15 | 1.14 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €100.07 Billion | €97.07 Billion | €99.12 Billion |
SINOPHARM GROUP 1/5/O.N. - Advanced Valuation Insights
This section examines the relationship between SINOPHARM GROUP 1/5/O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.59 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -0.6% |
| Total Assets | €390.36 Billion |
| Market Capitalization | $2.96 Billion USD |
Valuation Analysis
Below Book Valuation: The market values SINOPHARM GROUP 1/5/O.N.'s assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: SINOPHARM GROUP 1/5/O.N.'s assets decreased by 0.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for SINOPHARM GROUP 1/5/O.N. (2021–2025)
The table below shows the annual total assets of SINOPHARM GROUP 1/5/O.N. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €390.36 Billion ≈ $456.37 Billion |
-0.63% |
| 2024-12-31 | €392.83 Billion ≈ $459.26 Billion |
+2.46% |
| 2023-12-31 | €383.39 Billion ≈ $448.23 Billion |
+5.10% |
| 2022-12-31 | €364.78 Billion ≈ $426.46 Billion |
+8.75% |
| 2021-12-31 | €335.41 Billion ≈ $392.13 Billion |
-- |
About SINOPHARM GROUP 1/5/O.N.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more